Morgan Stanley adds Amazon.com as Top Pick
Investing.com - BTIG initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and a price target of $87.00 on Tuesday. The $256 million market cap company has seen remarkable growth, with shares surging over 1,600% in the past year. According to InvestingPro data, the stock currently trades above its Fair Value.
The research firm’s analysis focuses on MNPR’s development of ALXN1840, a novel copper binding therapy for the treatment of Wilson’s Disease, which was originally developed by AstraZeneca/Alexion before being licensed to Monopar.
BTIG describes the ALXN1840 program as "undervalued and underappreciated" by investors, citing positive Phase 2 and Phase 3 studies previously conducted by AstraZeneca/Alexion.
Monopar plans to submit a New Drug Application (NDA) for ALXN1840 in early 2026, according to the research note.
BTIG acknowledges regulatory risks but points to the therapy’s "highly favorable benefit/risk ratio" for patients, improvements over current standard of care, and the FDA’s emphasis on rare disease treatments as factors supporting potential approval in this area of "high unmet need."
In other recent news, Monopar Therapeutics has been the subject of several analyst reports highlighting the company’s developments. Cantor Fitzgerald reiterated its Overweight rating on Monopar, maintaining a price target of $74. This endorsement is based on support from the ALXN team in advancing Monopar’s drug toward regulatory approval. H.C. Wainwright initiated coverage of Monopar with a Buy rating and a $70 price target, focusing on the potential of ALXN1840, a drug for Wilson’s disease. Despite AstraZeneca’s previous termination of the drug’s development, H.C. Wainwright notes its superior copper mobilization and neurologic benefits in Phase 3 trials. Chardan Capital Markets also initiated coverage with a Buy rating, setting a $60 price target. The firm emphasized the potential of ALXN1840 and Monopar’s early-stage radiopharmaceutical pipeline. These developments reflect continued interest in Monopar’s drug pipeline and its potential impact on treating Wilson’s disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.